A blood test measuring levels of the GPR37 protein may help diagnose neuromyelitis optica spectrum disorder (NMOSD), assess disease severity, and monitor treatment response, according to a new study. The GPR37 test was also able to distinguish NMOSD from multiple sclerosis (MS) and other neurological disorders. “Our findings suggest that GPR37 may serve as a […] The post New GPR37 blood test predicts NMOSD severity, tracks treatment appeared first on Neuromyelitis News.
